Our results provide a basis for future investigations aiming at elucidating the molecular mechanisms underlying the expression or activity of E2F8 in prostate cancer, which assists to understand the role of E2F8 in CRPC biology and to develop novel cell cycle‐targeted therapeutic strategies. This evidence concerns the gene E2F8 and prostate carcinoma.